Related Experiment Video
Updated: Jul 23, 2025
Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
Expression profile of LncRNA ANRIL, miR-186, miR-181a, and MTMR-3 in patients with preeclampsia
Shymaa E Ayoub1, Olfat G Shaker2, Rehab Abdelhamid Aboshama3
1Department of Biochemistry and Molecular Biology, Faculty of Medicine, Fayoum University, Al Fayoum, Egypt.
Insights
Preeclampsia diagnosis may be improved using specific biomarkers. Researchers found altered levels of LncRNA ANRIL, miR-186, miR-181a, and MTMR-3 in preeclampsia patients, suggesting their diagnostic potential.
Area of Science:
- Biochemistry
- Molecular Biology
- Obstetrics
Background:
- Preeclampsia (PE) is a major global health concern, contributing significantly to maternal and neonatal mortality.
- Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) are implicated in the complex pathogenesis of preeclampsia.
Purpose of the Study:
- To investigate the expression profiles of serum LncRNA ANRIL, miR-186, miR-181a, and MTMR-3 in preeclampsia patients.
- To evaluate the potential of these molecules as diagnostic biomarkers for preeclampsia.
Main Methods:
- A case-control study involving 160 participants (80 preeclampsia patients and 80 controls).
- Quantitative analysis of serum LncRNA ANRIL, miR-186, miR-181a, and MTMR-3 expression levels.
- Receiver Operating Characteristic (ROC) curve analysis to assess diagnostic accuracy.
Main Results:
- Significant differences in expression were observed between preeclampsia and control groups.
- miR-186 and miR-181a showed significant upregulation (P < 0.0001 and P = 0.028, respectively).
- LncRNA ANRIL and MTMR-3 exhibited significant downregulation (P < 0.0001 for both).
Conclusions:
- Serum LncRNA ANRIL, miR-186, miR-181a, and MTMR-3 levels are significantly altered in preeclampsia.
- These molecules demonstrate potential as promising biomarkers for the diagnosis of preeclampsia.
Abstract:
Preeclampsia (PE) is a leading cause of maternal and neonatal morbidity and mortality worldwide. Several studies demonstrated the role of lncRNAs and miRNAs in the pathogenesis of preeclampsia; the aim was to detect the expression profiles of serum LncRNA ANRIL, miR-186, miR-181a, and MTMR-3 in patients with preeclampsia. The study included 160 subjects divided into 80 subjects considered as a control group, 80 patients with preeclampsia. We found that there was a significant difference between the preeclampsia and control groups with up-regulation of miR-186 median (IQR) = 4, 29 (1.35-7.73) (P < 0.0001), miR-181a median (IQR) = 2.45 (0.83-6.52) (P = 0.028), and downregulation of lncRNA ANRIL median (IQR) = 0.35(0.28-0.528) (P < 0.0001), MTMR median (IQR) = 0.32(0.155-1.11), (P < 0.0001). ROC curve of lncRNA ANRIL, miR-186, miR-181a, and MTMR-3 in preeclampsia patients showing the roles of these markers in the diagnosis of preeclampsia. In conclusion, serum LncRNA ANRIL, miR-186, miR-181a, and MTMR-3 could be promising biomarkers in the diagnosis of preeclampsia.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
01:22MicroRNAs